응고인자 : 시장 인사이트, 경쟁 구도 및 시장 예측(2034년)

Coagulation Factor Market Summary

Overview:

• The global coagulation factor market was valued at USD 7.20 billion in 2025 and is projected to reach USD 13.80 billion by 2034.
• The market is expected to expand at a CAGR of 7.5% during the forecast period 2026-2034, supported by the rising prevalence and improving diagnosis of hemophilia and bleeding disorders, the shift toward prophylaxis, and the advance of extended half-life and high-sustained factor products.
• By product type, the Factor VIII segment dominated the coagulation factor market with a 45% share in 2025.
• By technology, the recombinant segment dominated the coagulation factor market with a 65% share in 2025.
• By application, the hemophilia A segment dominated the coagulation factor market with a 48% share in 2025.
• By end-user, the hospitals and clinics segment dominated the coagulation factor market with a 50% share in 2025.
• North America accounted for the largest share of the coagulation factor market at 55% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

Coagulation factors are the proteins that mediate the clotting of blood, and the coagulation factor market comprises the therapeutic factor concentrates, both recombinant and plasma-derived, that are administered to replace a deficient or missing clotting factor in the treatment of hemophilia and other bleeding disorders. The scope of this report is the market for coagulation factor products, principally the recombinant and plasma-derived factor concentrates used to replace clotting factors; the non-factor therapies and gene therapies that also treat bleeding disorders are addressed as adjacent and competing categories. The market is organized upon the type of factor, the technology of production, the indication, and the setting of care. By product type, it spans Factor VIII, Factor IX, Factor VIIa, von Willebrand factor, Factor XIII, fibrinogen, the anti-inhibitor coagulant complex, and other factors, with Factor VIII holding the largest share. By technology, it divides between the recombinant factors produced through genetic engineering and the plasma-derived factors purified from donated plasma, with recombinant factors holding the larger share. By application, it spans hemophilia A, hemophilia B, von Willebrand disease, surgery, and other bleeding disorders, and by end-user it spans hospitals and clinics, home care settings, ambulatory surgical centers, and research institutes. The market is driven by the rising prevalence and improving diagnosis of bleeding disorders, the shift toward prophylactic treatment, and the advance of the extended half-life and high-sustained factor products that reduce the burden of treatment, and it is being reshaped by the competition of non-factor and gene therapies.

Coagulation Factor Market Key Growth Drivers

• The rising prevalence and improving diagnosis of hemophilia and other bleeding disorders, with the World Federation of Hemophilia identifying a large and growing diagnosed population worldwide, much of it still undiagnosed or untreated.
• The global shift toward prophylactic treatment, in which factor concentrates are administered regularly to prevent bleeds rather than only to treat them, substantially increases factor consumption per patient.
• Continuous technological advancement, including recombinant production, extended half-life factors, and the high-sustained factor products that deliver normal to near-normal factor activity with less frequent dosing.
• The expansion of access to treatment in the emerging economies, supported by rising healthcare investment and by the humanitarian aid programs that extend factor concentrates to previously untreated populations.
• The rising demand for factor concentrates in the management of bleeding in trauma, surgery, and acquired bleeding disorders, beyond the congenital hemophilias.
• The growth of plasma collection and fractionation infrastructure, which supports the supply of the plasma-derived factors that remain essential for several disorders.
• Rising healthcare expenditure and the well-developed reimbursement of rare bleeding disorders in the developed markets, which support the use of the high-cost factor therapies.

Key Companies in Coagulation Factor Market

The competitive landscape is led by the following active manufacturers:

• Takeda Pharmaceutical Company Limited
• CSL Limited (CSL Behring)
• Bayer AG
• Novo Nordisk A/S
• Pfizer Inc.
• Sanofi S.A.
• Octapharma AG
• Grifols, S.A.
• Swedish Orphan Biovitrum AB (Sobi)
• Kedrion Biopharma

Factors Contributing to the Growth of the Coagulation Factor Market

Market Drivers

Rising Prevalence and Improving Diagnosis of Bleeding Disorders

The foundational driver of the coagulation factor market is the rising prevalence and, above all, the improving diagnosis of hemophilia and other bleeding disorders, because the number of diagnosed and treated patients directly determines the demand for factor concentrates, and a large share of the affected population remains undiagnosed and untreated. Hemophilia A, the most common severe congenital bleeding disorder, occurs in about one in five thousand male births; hemophilia B and von Willebrand disease and the rarer factor deficiencies add to the burden, and the World Federation of Hemophilia has documented a large and growing diagnosed population worldwide while emphasizing that a substantial majority of the people with hemophilia in the world remain undiagnosed or without access to treatment. The improvement of diagnosis, through newborn screening, genetic testing, and the strengthening of hemophilia care, converts previously undiagnosed patients into treated patients requiring lifelong factor replacement, and the expansion of diagnosis and care in the emerging economies is a particularly large source of new demand. Each newly diagnosed and treated patient with severe hemophilia represents a lifelong and substantial course of factor treatment, so the improvement of diagnosis translates directly and durably into rising demand. Because the affected population is large, substantially undiagnosed, and requires lifelong treatment, and because diagnosis is improving, this driver provides the most durable foundation for market growth.

Shift Toward Prophylactic Treatment

The global shift toward prophylactic treatment is a powerful driver of the coagulation factor market, because prophylaxis, in which factor is administered regularly to prevent bleeds, consumes substantially more factor per patient than on-demand treatment of bleeds, and its adoption therefore increases factor consumption. Prophylaxis has become the standard of care for severe hemophilia in the developed markets, because the regular maintenance of a protective factor level prevents the spontaneous bleeds that cause the progressive and disabling joint damage of hemophilia, and the recognition of the superior long-term outcomes of prophylaxis has driven its adoption. Prophylactic treatment requires the regular, lifelong administration of factor concentrates, consuming far more factor than the episodic treatment of bleeds, and the migration of patients from on-demand to prophylactic treatment, and the extension of prophylaxis to more patients and to earlier initiation in childhood, substantially increase the demand for factor. The extension of prophylaxis into the emerging markets, as access and resources allow, represents a further large source of growth. While the newer extended half-life and high-sustained factors reduce the frequency of dosing, they maintain or increase the value of prophylaxis per patient. Because prophylaxis consumes more factor, is the standard of care, and is expanding, the shift toward it is a powerful driver of the volume and value of the market.

Market Restraints

Despite a large and rising treated population and continued innovation, the coagulation factor market faces several material constraints. The most significant and distinctive is the competition of the non-factor therapies and gene therapies, since the bispecific antibody emicizumab, which mimics the function of Factor VIII without being a factor, has been widely adopted for the prophylaxis of hemophilia A and displaces the Factor VIII prophylaxis that has been the largest segment of the factor market, and the gene therapies for hemophilia A and B, which aim to enable the patient to produce their own factor and thereby to reduce or eliminate the need for factor infusion, threaten over the longer term to reduce the demand for factor among treated patients, so that the factor market faces the erosion of its core prophylaxis demand by these alternatives even as it continues to grow through diagnosis, access, and premium innovation. A second constraint is the very high cost of factor therapy, which, while sustained by reimbursement in the developed markets, limits access in the emerging markets and attracts the pricing pressure and cost scrutiny that payers apply to an extraordinarily expensive category. A third constraint is the development of inhibitors, the neutralizing antibodies that some patients develop against infused factor, which complicate treatment, require the more expensive bypassing agents or immune tolerance induction, and reduce the effectiveness of factor replacement. Additional constraints include the dependence of the plasma-derived segment upon plasma supply, which can be disrupted; the burden of frequent intravenous infusion that factor therapy entails and that the non-factor therapies avoid; the limited access to diagnosis and treatment across much of the world; and the genericization and biosimilar competition that affects the older products. Together, these competitive, cost, and clinical factors ensure that growth, while positive, proceeds against genuine and intensifying constraint.

Coagulation Factor Market Segment Analysis

The coagulation factor market is segmented by product type (Factor VIII, Factor IX, Factor VIIa, von Willebrand factor, Factor XIII, fibrinogen, anti-inhibitor coagulant complex, and others), technology (recombinant and plasma-derived), application (hemophilia A, hemophilia B, von Willebrand disease, surgery, and other bleeding disorders), end-user (hospitals and clinics, home care settings, ambulatory surgical centers, and research institutes), and geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Product Type

Dominant Subsegment: Factor VIII.

The Factor VIII segment accounted for a 45% share of the coagulation factor market in 2025. Factor VIII dominates the product-type structure because hemophilia A, the deficiency of Factor VIII, is the most common of the severe congenital bleeding disorders, and the large treated population of hemophilia A, together with the prophylactic use of Factor VIII, makes it the largest factor by value. Hemophilia A occurs in about one in five thousand male births, some four times as commonly as hemophilia B, and the prophylactic treatment of the severe hemophilia A population consumes a very large volume of Factor VIII, sustaining the leading position of the segment; innovation in the segment, from recombinant to extended half-life to the high-sustained products, has both sustained its value and driven premiumization. Factor IX, used to treat hemophilia B, constitutes a substantial second category, and it has benefited particularly from the extended half-life products that exploit the favorable pharmacokinetics of Factor IX to achieve infrequent dosing. Von Willebrand factor, used to treat von Willebrand disease and often supplied in combination with Factor VIII, constitutes a further important category, and Factor VIIa, used as a bypassing agent in patients with inhibitors, the anti-inhibitor coagulant complex, fibrinogen, Factor XIII, and the other factors used in the rarer deficiencies and in acquired bleeding complete the structure. The Factor VIII segment is expected to retain its leading share throughout the forecast period, although it is the segment most exposed to the competition of the non-factor therapies.

By Technology

Dominant Subsegment: Recombinant.

The recombinant segment accounted for a 65% share of the coagulation factor market in 2025. The recombinant technology dominates the technology structure because recombinant factors have become the preferred treatment for hemophilia in the developed markets, valued for their independence from donated plasma and the associated freedom from the risk of transmitted infection, and the migration toward them, together with the premium value of the recombinant extended half-life and high-sustained products, makes recombinant the larger and higher-value segment. Recombinant factors are produced through genetic engineering rather than purified from plasma, which removes the dependence upon plasma supply and the historical risk of the transmission of infection that affected the early plasma-derived products, and this safety and supply advantage has driven their adoption as the standard of care for hemophilia A and B in the developed markets. The innovation in the field, from recombinant to extended half-life to high-sustained products, has been concentrated in the recombinant segment, sustaining its value and its leading position. The plasma-derived technology constitutes the second segment, and it remains essential for von Willebrand disease, for the rarer factor deficiencies for which no recombinant product exists, for the anti-inhibitor and prothrombin complex concentrates, and for the large share of the emerging markets where plasma-derived factors are more affordable and available, so it retains a substantial and enduring role. The recombinant segment is expected to retain its leading share throughout the forecast period.

Coagulation Factor Market Region Analysis

Dominant Region: North America

North America accounted for a 55% share of the global coagulation factor market in 2025. The region is expected to account for the largest share of the global market, driven by the rising prevalence and high diagnosis of bleeding disorders, the well-developed reimbursement and high healthcare expenditure that support the extraordinary cost of factor therapy, the high adoption of prophylaxis and of premium recombinant and high-sustained products, the strong plasma collection infrastructure, and the presence and commercial strength of the leading companies. The United States is the largest and highest-value market for coagulation factors in the world by a wide margin, reflecting the high rate of diagnosis, the near-universal adoption of prophylaxis for severe hemophilia, the use of the premium recombinant and extended half-life and high-sustained products, and, above all, the high price of factor therapy and the comprehensive reimbursement that covers it, and the United States accounts for a disproportionate share of global factor value. The region combines a well-developed network of hemophilia treatment centers, high diagnosis and treatment rates, and the strongest reimbursement in the world with a strong plasma collection infrastructure and the presence of the leading manufacturers, and it is the principal market for the newest and most valuable products. The region is expected to retain its dominant position throughout the forecast period, though it is also the region where the non-factor and gene therapies most erode factor demand.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the coagulation factor market through 2034. The region is emerging as the principal growth engine of the market, propelled by very large populations, a large and substantially undiagnosed and untreated population of people with bleeding disorders, expanding diagnosis and access, rising healthcare investment, and the growth of local manufacturing and humanitarian aid. The region carries an enormous population of people with hemophilia and bleeding disorders, a large majority of whom have historically been undiagnosed or without adequate access to factor, and the expansion of diagnosis, care, and access, supported by rising healthcare investment, by government programs, and by the humanitarian aid programs that donate factor to previously untreated populations, is converting this large untreated population into treated patients requiring factor. The very large populations of China and India, combined with their historically low treatment rates and their rising healthcare investment, create substantial and rapidly growing demand, and the growth of local diagnosis, care, reimbursement, and manufacturing reinforces it. China combines a very large population with rising investment and a growing domestic industry; India combines a very large population and bleeding-disorder burden with expanding access and humanitarian support, and Japan combines an advanced healthcare system with high adoption of the premium products. The coexistence of demand for both affordable plasma-derived and premium recombinant products creates opportunity across the market. Regional growth is expected to exceed the global average across every segment. Source: World Federation of Hemophilia.

Regional Commentary

North America

North America leads on value and adoption, holding a 55% share in 2025. The region combines high diagnosis, near-universal prophylaxis for severe hemophilia, high adoption of premium recombinant and high-sustained products, strong plasma infrastructure, and the strongest reimbursement in the world, which sustains the extraordinary cost of factor therapy, with the United States accounting for a disproportionate share of global factor value. Near-term dynamics are shaped by the competition of non-factor and gene therapies, the uptake of high-sustained factor products, and the pricing scrutiny of an extraordinarily expensive category.

Europe

Europe is a large and sophisticated market, and the home region of several of the leading companies, including major plasma-fractionation and biopharmaceutical firms, and it combines well-developed healthcare systems, high diagnosis and treatment rates, broad reimbursement, and a strong tradition of hemophilia care, with Germany, France, the United Kingdom, Italy, and Spain as principal markets. The region combines high adoption of prophylaxis and of the premium products with the health-technology assessment and pricing negotiation that shape access, and it hosts distinctive plasma-fractionation and recombinant manufacturers. The competition of non-factor and gene therapies and the emphasis upon cost-effectiveness shape the market, which is served by both global and regional participants.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by very large populations, a large and substantially undiagnosed and untreated bleeding-disorder population, expanding diagnosis and access, rising healthcare investment, and the growth of local manufacturing and humanitarian aid. The expansion of diagnosis and access is converting a large untreated population into treated patients requiring factor. China combines a very large population with rising investment and a growing domestic industry; India combines a very large population and burden with expanding access and humanitarian support, and Japan combines an advanced system with high adoption of premium products. Both affordable plasma-derived and premium recombinant products find demand. Growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. The burden of bleeding disorders is significant across all three, and a large share of the affected population remains undiagnosed or without adequate access to factor, creating substantial unmet need. The Gulf states combine high healthcare investment with good access to premium products, and the larger Latin American markets, particularly Brazil, support established hemophilia care programs and growing access, together representing steady growth. Much of Africa faces severe constraints in diagnosis, care, and access, so treatment depends heavily upon humanitarian aid and plasma-derived products and is concentrated in the larger urban centers, with very substantial unmet need. Regional growth will be driven by expanding diagnosis and access, rising investment, humanitarian aid, and the availability of both affordable plasma-derived and, increasingly, recombinant products.

Coagulation Factor Market Competitive Landscape

The global coagulation factor market is classified as Consolidated. The market is led by a group of large biopharmaceutical and plasma-fractionation companies, principally Takeda, CSL Behring, Bayer, Novo Nordisk, Pfizer, Sanofi, Octapharma, and Grifols, whose established recombinant and plasma-derived factor portfolios, global manufacturing, and deep expertise in bleeding disorders give them the large majority of the market. Competition centers upon the innovation of the factor product, principally the extended half-life and high-sustained technologies, upon the breadth of the factor portfolio, upon plasma collection and manufacturing scale, upon relationships with the hemophilia treatment centers, and increasingly upon the defense of factor against the competing non-factor and gene therapies. The competitive landscape is evaluated across the following dimensions:

• Market concentration: Consolidated, with a group of large biopharmaceutical and plasma-fractionation companies holding the large majority of the market, and with the recombinant and plasma-manufacturing scale, the portfolio breadth, the clinical expertise, and the regulatory capability of the leaders constituting a high barrier to entry, complemented by regional and emerging manufacturers.
• Leading players: Takeda leads through its broad recombinant and plasma-derived portfolio, CSL Behring through its recombinant and plasma factors and its broader plasma franchise, Bayer and Novo Nordisk through their recombinant Factor VIII and other products, Pfizer through its recombinant factors, Sanofi and Sobi through their extended half-life and high-sustained products, and Octapharma and Grifols through their recombinant and plasma-derived factors, with a set of regional manufacturers serving domestic markets.
• Geographic reach: The leading companies maintain global commercial, manufacturing, and plasma-collection organizations, decisive because coagulation factors are a global market requiring broad reach, local regulatory approval, and reliable supply, while regional manufacturers serve domestic and cost-sensitive markets and the humanitarian aid programs extend factor to the least-served populations.
• Product portfolio strength: Competitive advantage rests upon the innovation of the factor product, principally the extended half-life and high-sustained technologies that reduce the burden of treatment, upon the breadth of the portfolio across the factors and the recombinant and plasma-derived technologies, and upon the plasma collection and manufacturing scale that secures supply, with the leaders differentiating through premium products and comprehensive portfolios.
• Pipeline strength: Development is concentrated in the high-sustained and next-generation factor products that extend dosing intervals and raise factor activity, in the defense and differentiation of factor against the non-factor and gene therapies, and, among several of the leaders, in the non-factor therapies and gene therapies themselves, which the factor companies are also developing.
• Strategic partnerships: Collaboration spans the co-development and co-commercialization of factor products, exemplified by the long-standing collaboration between two companies on extended half-life and high-sustained factors across their respective territories, partnerships for plasma supply and manufacturing, and the licensing and distribution arrangements through which factors reach diverse geographies.
• M&A activity: Acquisition and consolidation have shaped the field, including the major acquisitions that assembled the leading hemophilia franchises, the acquisition of recombinant and gene therapy capability, and the strategic positioning of the plasma-fractionation and biopharmaceutical leaders across factor, non-factor, and gene therapy.
• Innovation focus: Innovation is shifting toward the high-sustained factor products that deliver near-normal factor activity with infrequent dosing, the defense of factor against the non-factor therapies through improved convenience and value, and, in parallel, the development by several of the leaders of the non-factor and gene therapies that compete with factor, positioning them across the treatment landscape.
• Regulatory standing: Regulatory approval for factor products in the major jurisdictions, including approvals from the Food and Drug Administration, the European Medicines Agency, and the Japanese authorities, together with the orphan and breakthrough designations that support the rare-disease products, is a decisive credential, and the stringent regulation of the biologics and plasma products that constitute the market rewards the scale and regulatory capability of the leading companies.

Coagulation Factor Market Recent Developmental Activities

In June 2024, Sanofi and Sobi received European Commission approval for their high-sustained Factor VIII therapy efanesoctocog alfa, marketed as ALTUVOCT in Europe and as ALTUVIIIO in other territories, for the treatment and prevention of bleeds and perioperative management in hemophilia A. Strategic significance: the European approval extended a first-in-class high-sustained Factor VIII therapy to a major region and reinforced the strategy of defending and premiumizing the Factor VIII segment through the innovation of high-sustained products against the competition of non-factor therapies.

Coagulation Factor Market Segmentation

Coagulation Factor Market Assessment by Product Type

• Factor VIII
• Factor IX
• Factor VIIa
• von Willebrand Factor
• Factor XIII
• Fibrinogen
• Anti-Inhibitor Coagulant Complex
• Others

Coagulation Factor Market Assessment by Technology

• Recombinant
• Plasma-Derived

Coagulation Factor Market Assessment by Application

• Hemophilia A
• Hemophilia B
• von Willebrand Disease
• Surgery
• Other Bleeding Disorders

Coagulation Factor Market Assessment by End-User

• Hospitals and Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Research Institutes

Coagulation Factor Market Assessment by Geography

• North America
• United States Coagulation Factor Market Size in USD million (2023-2034)
• Canada Coagulation Factor Market Size in USD million (2023-2034)
• Mexico Coagulation Factor Market Size in USD million (2023-2034)
• Europe
• France Coagulation Factor Market Size in USD million (2023-2034)
• Germany Coagulation Factor Market Size in USD million (2023-2034)
• United Kingdom Coagulation Factor Market Size in USD million (2023-2034)
• Italy Coagulation Factor Market Size in USD million (2023-2034)
• Spain Coagulation Factor Market Size in USD million (2023-2034)
• Rest of Europe Coagulation Factor Market Size in USD million (2023-2034)
• Asia-Pacific
• China Coagulation Factor Market Size in USD million (2023-2034)
• Japan Coagulation Factor Market Size in USD million (2023-2034)
• India Coagulation Factor Market Size in USD million (2023-2034)
• Australia Coagulation Factor Market Size in USD million (2023-2034)
• South Korea Coagulation Factor Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Coagulation Factor Market Size in USD million (2023-2034)
• Rest of the World
• Middle East Coagulation Factor Market Size in USD million (2023-2034)
• Africa Coagulation Factor Market Size in USD million (2023-2034)
• South America Coagulation Factor Market Size in USD million (2023-2034)

Key Takeaways from the Coagulation Factor Market Report Study

• Market size analysis for the current Coagulation Factor market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global Coagulation Factor market.
• Various opportunities available for competitors in the Coagulation Factor market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current Coagulation Factor market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for Coagulation Factor market growth in the future?

Target audience that can benefit from this Coagulation Factor market report study

• Coagulation Factor product providers
• Research organizations and consulting companies
• Coagulation Factor -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Coagulation Factor
• Various end-users who want to know more about the Coagulation Factor market and the latest technological developments in the Coagulation Factor market.

Frequently Asked Questions:

Q1. At what rate is the coagulation factor market expected to grow?

The global coagulation factor market is projected to grow at a compound annual growth rate of 7.5% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the coagulation factor market?

The global coagulation factor products market was valued at USD 7.20 billion in 2025 and is projected to reach USD 13.80 billion by 2034.

Q3. Which region dominates the coagulation factor market?

North America dominated the coagulation factor market with a 55% share in 2025 on a modeled basis, driven by high diagnosis, near-universal prophylaxis for severe hemophilia, high adoption of premium recombinant and high-sustained products, strong plasma infrastructure, and, above all, the high price of factor therapy and the comprehensive reimbursement that sustains it, with the United States accounting for a disproportionate share of global factor value. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by very large populations, a large undiagnosed and untreated population, expanding diagnosis and access, and rising healthcare investment.

Q4. What are the key factors driving growth in the coagulation factor market?

The principal drivers are the rising prevalence and improving diagnosis of hemophilia and bleeding disorders; the shift toward prophylactic treatment, which consumes more factor per patient; continuous technological advancement in recombinant, extended half-life, and high-sustained factors; the expansion of access in emerging markets, supported by humanitarian aid; the demand for factor in trauma, surgery, and acquired bleeding; the growth of plasma collection and fractionation; and healthcare expenditure and reimbursement, tempered by the intensifying competition of non-factor and gene therapies.

Q5. Who are the major players in the coagulation factor market?

The market is consolidated and led by Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Bayer AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Octapharma AG, and Grifols, S.A., together with Swedish Orphan Biovitrum AB (Sobi) and Kedrion Biopharma. Additional participants include LFB Group, Biotest AG, GC Biopharma Corp., Kamada Ltd., and China Biologic Products Holdings. The non-factor therapy emicizumab and the gene therapies for hemophilia are competing categories rather than coagulation factor products.

Table of Contents

1. Coagulation Factor Market Introduction

• 1.1. Scope of the Report (Coagulation Factor Products)
• 1.2. Market Segmentation
• 1.3. Market Overview at a Glance

2. Coagulation Factor Market Executive Summary

• 2.1. Key Highlights and Market Snapshot

3. Coagulation Factor Market Key Factors Analysis

• 3.1. Market Drivers
  • 3.1.1. Rising Prevalence and Improving Diagnosis
  • 3.1.2. Shift Toward Prophylactic Treatment
  • 3.1.3. Technological Advancement in Factor Products
  • 3.1.4. Expansion of Access in Emerging Markets
• 3.2. Market Restraints
  • 3.2.1. Competition of Non-Factor and Gene Therapies
  • 3.2.2. High Cost of Factor Therapy
  • 3.2.3. Inhibitor Development
• 3.3. Market Opportunities
  • 3.3.1. High-Sustained and Next-Generation Factors
  • 3.3.2. Emerging Markets and Expanding Access

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1. The United States
• 5.2. Europe
• 5.3. Japan
• 5.4. China

6. Coagulation Factor Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Coagulation Factor Market Assessment

• 7.1. By Product Type
  • 7.1.1. Factor VIII
  • 7.1.2. Factor IX
  • 7.1.3. Factor VIIa
  • 7.1.4. von Willebrand Factor
  • 7.1.5. Factor XIII
  • 7.1.6. Fibrinogen
  • 7.1.7. Anti-Inhibitor Coagulant Complex
  • 7.1.8. Others
• 7.2. By Technology
  • 7.2.1. Recombinant
  • 7.2.2. Plasma-Derived
• 7.3. By Application
  • 7.3.1. Hemophilia A
  • 7.3.2. Hemophilia B
  • 7.3.3. von Willebrand Disease
  • 7.3.4. Surgery
  • 7.3.5. Other Bleeding Disorders
• 7.4. By End-User
  • 7.4.1. Hospitals and Clinics
  • 7.4.2. Home Care Settings
  • 7.4.3. Ambulatory Surgical Centers
  • 7.4.4. Research Institutes
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. United States Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.1.2. Canada Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.1.3. Mexico Coagulation Factor Market Size in USD million (2023-2034)
  • 7.5.2. Europe
    • 7.5.2.1. France Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.2.2. Germany Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.2.3. United Kingdom Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.2.4. Italy Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.2.5. Spain Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.2.6. Rest of Europe Coagulation Factor Market Size in USD million (2023-2034)
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. China Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.3.2. Japan Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.3.3. India Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.3.4. Australia Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.3.5. South Korea Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.3.6. Rest of Asia-Pacific Coagulation Factor Market Size in USD million (2023-2034)
  • 7.5.4. Rest of the World
    • 7.5.4.1. Middle East Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.4.2. Africa Coagulation Factor Market Size in USD million (2023-2034)
    • 7.5.4.3. South America Coagulation Factor Market Size in USD million (2023-2034)

8. Coagulation Factor Market Competitive Landscape

• 8.1. Competitive Analysis
• 8.2. Company Share Analysis (Premium Offering)

9. Coagulation Factor Market Investment and Commercial Trends

10. Coagulation Factor Market Company and Product Profiles

• 10.1. Takeda Pharmaceutical Company Limited
  • 10.1.1. Company Overview
  • 10.1.2. Company Snapshot
  • 10.1.3. Financial Overview
  • 10.1.4. Product Listing
  • 10.1.5. Strategic Initiatives / Entropy
• 10.2. CSL Limited (CSL Behring)
  • 10.2.1. Company Overview
  • 10.2.2. Company Snapshot
  • 10.2.3. Financial Overview
  • 10.2.4. Product Listing
  • 10.2.5. Strategic Initiatives / Entropy
• 10.3. Bayer AG
  • 10.3.1. Company Overview
  • 10.3.2. Company Snapshot
  • 10.3.3. Financial Overview
  • 10.3.4. Product Listing
  • 10.3.5. Strategic Initiatives / Entropy
• 10.4. Novo Nordisk A/S
  • 10.4.1. Company Overview
  • 10.4.2. Company Snapshot
  • 10.4.3. Financial Overview
  • 10.4.4. Product Listing
  • 10.4.5. Strategic Initiatives / Entropy
• 10.5. Pfizer Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Snapshot
  • 10.5.3. Financial Overview
  • 10.5.4. Product Listing
  • 10.5.5. Strategic Initiatives / Entropy
• 10.6. Sanofi S.A.
  • 10.6.1. Company Overview
  • 10.6.2. Company Snapshot
  • 10.6.3. Financial Overview
  • 10.6.4. Product Listing
  • 10.6.5. Strategic Initiatives / Entropy
• 10.7. Octapharma AG
  • 10.7.1. Company Overview
  • 10.7.2. Company Snapshot
  • 10.7.3. Financial Overview
  • 10.7.4. Product Listing
  • 10.7.5. Strategic Initiatives / Entropy
• 10.8. Grifols, S.A.
  • 10.8.1. Company Overview
  • 10.8.2. Company Snapshot
  • 10.8.3. Financial Overview
  • 10.8.4. Product Listing
  • 10.8.5. Strategic Initiatives / Entropy
• 10.9. Swedish Orphan Biovitrum AB (Sobi)
  • 10.9.1. Company Overview
  • 10.9.2. Company Snapshot
  • 10.9.3. Financial Overview
  • 10.9.4. Product Listing
  • 10.9.5. Strategic Initiatives / Entropy
• 10.10. Kedrion Biopharma
  • 10.10.1. Company Overview
  • 10.10.2. Company Snapshot
  • 10.10.3. Financial Overview
  • 10.10.4. Product Listing
  • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us